Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 25 of 273

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]Technology appraisal guidanceTBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Technology appraisal guidanceTBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]Technology appraisal guidanceTBC
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer ID6368Technology appraisal guidanceTBC
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC
Alzheimer's disease (early) - gantenerumab [ID6142]Technology appraisal guidanceTBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Technology appraisal guidance
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Technology appraisal guidanceTBC
Atogepant for preventing migraine [ID5090]Technology appraisal guidance
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avapritinib for treating advanced systemic mastocytosis ID3770Technology appraisal guidance
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
AZD 3152 for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All